down arrow

Betta Pharmaceuticals Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100002DD9
CNY
47.38
-0.92 (-1.9%)

Dec 04

SHE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Betta Pharmaceuticals Co., Ltd.
Why is Betta Pharmaceuticals Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 12.38% and Operating profit at 4.42% over the last 5 years
2
Negative results in Jun 25
  • INTEREST(HY) At CNY 38.89 MM has Grown at 74.59%
  • PRE-TAX PROFIT(Q) At CNY 67.42 MM has Fallen at -48.76%
  • RAW MATERIAL COST(Y) Grown by 12.08% (YoY)
3
With ROE of 6.92%, it has a very expensive valuation with a 4.95 Price to Book Value
  • Over the past year, while the stock has generated a return of 8.66%, its profits have fallen by -5.2%
  • At the current price, the company has a high dividend yield of 0.3
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Betta Pharmaceuticals Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Betta Pharmaceuticals Co., Ltd.
-17.49%
0.97
47.70%
China Shanghai Composite
14.77%
1.01
15.10%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
12.38%
EBIT Growth (5y)
4.42%
EBIT to Interest (avg)
9.58
Debt to EBITDA (avg)
1.94
Net Debt to Equity (avg)
0.31
Sales to Capital Employed (avg)
0.35
Tax Ratio
5.06%
Dividend Payout Ratio
20.68%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.85%
ROE (avg)
7.69%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
72
Industry P/E
Price to Book Value
4.95
EV to EBIT
63.93
EV to EBITDA
31.49
EV to Capital Employed
3.99
EV to Sales
9.54
PEG Ratio
NA
Dividend Yield
0.30%
ROCE (Latest)
6.24%
ROE (Latest)
6.92%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
NET SALES(9M)

At CNY 2,252.34 MM has Grown at 18.34%

INVENTORY TURNOVER RATIO(HY)

Highest at 2.69%

-16What is not working for the Company
INTEREST(HY)

At CNY 38.89 MM has Grown at 74.59%

PRE-TAX PROFIT(Q)

At CNY 67.42 MM has Fallen at -48.76%

RAW MATERIAL COST(Y)

Grown by 12.08% (YoY

OPERATING PROFIT MARGIN(Q)

Lowest at 25.63 %

NET PROFIT(Q)

Lowest at CNY 39.48 MM

Here's what is working for Betta Pharmaceuticals Co., Ltd.
Inventory Turnover Ratio
Highest at 2.69% and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Net Sales
At CNY 2,252.34 MM has Grown at 18.34%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

Here's what is not working for Betta Pharmaceuticals Co., Ltd.
Interest
At CNY 38.89 MM has Grown at 74.59%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Profit
At CNY 39.48 MM has Fallen at -67.82%
over average net sales of the previous four periods of CNY 122.66 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (CNY MM)

Pre-Tax Profit
At CNY 67.42 MM has Fallen at -48.76%
over average net sales of the previous four periods of CNY 131.57 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Operating Profit Margin
Lowest at 25.63 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Net Profit
Lowest at CNY 39.48 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (CNY MM)

Raw Material Cost
Grown by 12.08% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Non Operating Income
Highest at CNY 0.2 MM
in the last five periods
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating income

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."